Schedule 13D ownership disclosure

Oruka Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 687604108

Event date: 2025-03-06

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Fairmount Funds Management LLCReported CIK 0001802528

    Shares: 8,511,824.00 · Class: 19.99%

  • Fairmount Healthcare Fund II L.P.Reported CIK 0001769651

    Shares: 5,938,516.00 · Class: 13.95%

  • Fairmount Healthcare Co-Invest III L.P.Reported CIK 0002009690

    Shares: 2,573,308.00 · Class: 6.87%

  • Peter Evan HarwinReported CIK 0001663607

    Shares: 8,511,824.00 · Class: 19.99%

  • Tomas KiselakReported CIK 0001830177

    Shares: 8,511,824.00 · Class: 19.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-022364
Form type
SCHEDULE 13D/A
Filer
Fairmount Funds Management LLC
CIK
CIK 1802528
Filed
Mar 10, 2025
Reporting period
Mar 06, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub